Variable Delta-9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics After Cannabis Smoking in Regular Users

被引:1
|
作者
Liyanage, Marlon [1 ]
Nikanjam, Mina [2 ]
Capparelli, Edmund V. [1 ]
Suhandynata, Raymond T. [1 ]
Fitzgerald, Robert L. [3 ]
Marcotte, Thomas D. [4 ]
Grant, Igor [4 ]
Momper, Jeremiah D. [1 ,5 ]
机构
[1] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Louisiana Jolla, CA USA
[2] Univ Calif San Diego, Div Hematol Oncol, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Ctr Adv Lab Med, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Ctr Med Cannabis Res CMCR, Dept Psychiat, La Jolla, CA 92093 USA
[5] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr, MC 0657, La Jolla, CA 92093 USA
关键词
cannabis; tetrahydrocannabinol; pharmacokinetics; THC; PERFORMANCE; MARIJUANA; HEAVY;
D O I
10.1097/FTD.0000000000001104
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Supplemental Digital Content is Available in the Text. Background:Despite its federally restricted status, cannabis is widely used medicinally and recreationally. The pharmacokinetics (PK) and central nervous system (CNS) effects of tetrahydrocannabinol (THC), the major psychoactive cannabinoid, are not well understood. The objective of this study was to develop a population PK model of inhaled THC, including sources of variability, and to conduct an exploratory analysis of potential exposure-response relationships.Methods:Regular adult cannabis users smoked a single cannabis cigarette containing 5.9% THC (Chemovar A) or 13.4% THC (Chemovar B) ad libitum. THC concentrations in whole blood were measured and used to develop a population PK model to identify potential factors contributing to interindividual variability in THC PK and to describe THC disposition. Relationships between model-predicted exposure and heart rate, change in composite driving score on a driving simulator, and perceived highness were evaluated.Results:From the 102 participants, a total of 770 blood THC concentrations were obtained. A two-compartment structural model adequately fit the data. Chemovar and baseline THC (THCBL) were found to be significant covariates for bioavailability, with Chemovar A having better THC absorption. The model predicted that heavy users-those with the highest THCBL-would have significantly higher absorption than those with lighter previous use. There was a statistically significant relationship between exposure and heart rate, and exposure and perceived highness.Conclusions:THC PK is highly variable and related to baseline THC concentrations and different chemovars. The developed population PK model showed that heavier users had higher THC bioavailability. To better understand the factors affecting THC PK and dose-response relationships, future studies should incorporate a wide range of doses, multiple routes of administration, and different formulations relevant to typical community use.
引用
收藏
页码:689 / 696
页数:8
相关论文
共 50 条
  • [1] PLASMA KINETICS OF DELTA-9-TETRAHYDROCANNABINOL AFTER CANNABIS SMOKING
    SCHERRMANN, JM
    HOELLINGER, H
    NAM, NH
    TOXICOLOGY LETTERS, 1980, : 90 - 90
  • [2] PHARMACOKINETICS OF DELTA-9-TETRAHYDROCANNABINOL IN DOGS
    GARRETT, ER
    HUNT, CA
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (03) : 395 - 407
  • [3] Cannabis users are less sensitive to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol administration
    Colizzi, M.
    Giampietro, V.
    Brammer, M.
    McGuire, P.
    Bhattacharyya, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S85 - S86
  • [4] Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia
    Amir I. A. Ahmed
    Geke A. H. van den Elsen
    Angela Colbers
    Cornelis Kramers
    David M. Burger
    Marjolein A. van der Marck
    Marcel G. M. Olde Rikkert
    Psychopharmacology, 2015, 232 : 2587 - 2595
  • [5] Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia
    Ahmed, Amir I. A.
    van den Elsen, Geke A. H.
    Colbers, Angela
    Kramers, Cornelis
    Burger, David M.
    van der Marck, Marjolein A.
    Rikkert, Marcel G. M. Olde
    PSYCHOPHARMACOLOGY, 2015, 232 (14) : 2587 - 2595
  • [6] Do cannabis users develop tolerance for the psychoactive effects of delta-9-tetrahydrocannabinol? An fMRI study
    Colizzi, M.
    McGuire, P.
    Giampietro, V.
    Williams, S.
    Brammer, M.
    Bhattacharyya, S.
    EUROPEAN PSYCHIATRY, 2018, 48 : S333 - S333
  • [7] EFFECTS OF INTRAVENOUS DELTA-9-TETRAHYDROCANNABINOL (CANNABIS) ON HUMAN ELECTROENCEPHALOGRAM
    RAMANI, V
    KANAKIS, C
    CLINICAL ELECTROENCEPHALOGRAPHY, 1976, 7 (02): : 92 - 94
  • [8] Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms
    Budney, Alan J.
    Vandrey, Ryan G.
    Hughes, John R.
    Moore, Brent A.
    Bahrenburg, Betsy
    DRUG AND ALCOHOL DEPENDENCE, 2007, 86 (01) : 22 - 29
  • [9] Determination of delta-9-tetrahydrocannabinol content of cannabis seizures in Egypt
    Souleman, Ahmed M. A.
    Gaafar, Alaa El-Din M.
    Abdel-Salami, Omar M.
    ElShebiney, Shaimaa A.
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2017, 10 (03) : 291 - 294
  • [10] Delta-9-Tetrahydrocannabinol acetate from acetylation of cannabis oil
    Valentine, MD
    SCIENCE & JUSTICE, 1996, 36 (03) : 195 - 197